Molecular changes of colorectal cancer in Singapore

Annals of the Academy of Medicine Singapore

Volumn 25, Issue 1, 1996, Pages 3-10

  Goh, H S ^a,c   Khine, K ^b   Elnatan, J ^b   Yao, J ^b   Smith, D R ^b  

^a Gleneagles Medical Centre

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c GLENEAGLES HOSPITAL   (Singapore)

Author keywords

Allelic loss; Apoptosis; Mutation; Proto oncogene; Tumour suppressor

Indexed keywords

ADENOCARCINOMA; ASIAN; COLORECTAL TUMOR; ETHNOLOGY; GENETICS; HUMAN; MOLECULAR BIOLOGY; MUTATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTO ONCOGENE; REVIEW; SINGAPORE; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ASIAN CONTINENTAL ANCESTRY GROUP; COLORECTAL NEOPLASMS; GENES, TUMOR SUPPRESSOR; HUMANS; MOLECULAR BIOLOGY; MUTATION; PROTO-ONCOGENES; SINGAPORE;

EID: 0029691636     PISSN: 03044602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (93)

1. Lee H P, Day N E, Shanmugaratnam K. Trends in cancer incidence in Singapore 1968-1982. Lyon, France. International Agency for Research on Cancer, 1988.
2. Nagata Y, Abe M, Kobayashi K, Yoshida K, Ishibashi T, Naoe I, et al Glycine to Aspartic acid mutations at codon 13 of the c-Ki-ras gene in human gastrointestinal cancers. Cancer Res 1990; 50:480-2.
3. Kikuchi-Yanoshita R, Motoko M, Seki M, Tanaka K, Maeda Y, Kino H, et al. Genetic changes of both p53 alleles associated with the conversion from colorectal adenoma to early carcinoma in familial adenomatous polyposis and non familial adenomatous polyposis patients Cancer Res 1992; 52:3965-71.
4. Rothberg P G, Spandorfer J M, Erisman M D, Staroscik R N, Sears H F, Petersen R O, et al. Evidence that c-myc expression defines two genetically distinct forms of colorectal adenocarcinoma Br J Cancer 1985; 52:629-32
5. Imaseki H, Hayashi H, Taira M, Ito Y, Tabata Y, Onoda S, et al. Expression of c-myc oncogene in colorectal polyps as a biological marker for monitoring malignant potential. Cancer 1991; 64:704-9.
6. Norwell P C. The clonal evolution of tumour cell populations Science 1976; 194:23-8.
7. Hansen M F, Cavanee W K Genetics of cancer predisposition. Cancer Res 1987; 47:5518-27.
8. Fearon E R, Jones P A. Progressing towards a molecular description of colorectal cancer development. FASEB J 1992; 6:2783-90
9. Fearon E R, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-67.
10. Venstrom B, Sheiness D, Zabielski J, Bishop J. Isolation and characterisation of c-myc, a cellular homologue of the oncogene (v-myc) of avian myelocytomatosis virus, strain 29. J Virol 1982; 42:773-9.
11. DePinho R A, Mitsock L, Hatton K, Ferrier P, Zimmerman K, LeGouy E, et al. myc family of cellular oncogenes J Cell Biochem 1987; 33:257-66.
12. DePinho R A, Schreiber-Agus N, Alt F W. myc family oncogenes in the development of normal and neoplastic cells. Adv Cancer Res 1991; 57:1-46.
13. Morgenbesser S D, DePinho R A. Use of transgenic mice to study myc family gene function in normal mammalian development and in cancer. Sennin Cancer Biol 1994; 5:21-36.
14. Canman C E, Kastan M B. Induction of apoptosis by tumor suppressor genes and oncogenes Semin Cancer Biol 1995; 6 17-25.
15. Erisman M D, Litwin S, Keichan R D, Comis R L, Astrin S M. Noncorrelation of the expression of the c-myc oncogene in colorectal carcinoma with recurrence of the disease or patient survival. Cancer Res 1988; 48:1350-5
16. Tsuboi K, Hirayoshi K, Takeuchi K, Sabe H, Shimada Y, Ohshio G, et al. Expression of c-myc gene in human gastrointestinal malignancies. Biochem Biophys Res Commun 1987; 146:699-704
17. Smith D R, Myint T, Goh H-S. Over-expression of the c-myc proto-oncogene in colorectal carcinoma. Br J Cancer 1993; 68.407-13.
18. Smith D R, Goh H-S Over-expression of the c-myc proto-oncogene in colorectal carcinoma is associated with a reduced mortality that is abrogated by point mutation of the p53 tumour suppressor gene. Clin Cancer Res 1996. (In press)
19. Wyllie A H, Rose K A, Morris R G, Steel C M, Foster E, Spandidos D A Rodent fibroblast tumors expressing human myc and ras genes: growth, metastasis and endogenous oncogene expression. Br J Cancer 1987; 56 251-9.
20. Arrends M J, McGregor A H, Wyllie A H. Apoptosis is inversely related to necrosis and determines net growth in tumors bearing constitutively expressed myc, ras and HPV oncogenes. Am J Pathol 1994; 144:1045-57.
21. Barbacid M. ras genes. Annu Rev Biochem 1987; 56.779-827.
22. Bos J L. ras oncogenes in human cancer: A review. Cancer Res 1989; 49:4682-9.
23. Grand R J A, Owens D. The biochemistry of ras p21. Biochem J 1991; 279:609-31.
24. Willingham M C, Pastan I M, Shih T Y, Scolnick E M. Localisation of the src gene product of the harvey strain MSV to plasma membrane of transformed cells by electron microscopic immunocytochemistry. Cell 1980; 19:1005-14.
25. Yanez L, Groffen J, Valenzuela D M. c-K-ras mutations in human carcinomas occur preferentially in codon 12. Oncogene 1987; 1:315-8
26. Bos J L, Fearon E R, Hamilton S R, Verlaan-deVries M, vanBoom J H, van der Eb A J, et al. Prevalence of ras gene mutations in human colorectal cancers Nature 1987; 327:293-7.
27. Forrester K, Almoguera C, Han K, Grizzle W E, Perucho M. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 1987; 327:298-303.
28. Burmer G C, Levine D S, Kulander B G, Haggitt R C, Rubin C E, Rabinovitch P S. c-Ki-ras mutations in chronic ulcerative colitis and sporadic colon carcinoma. Gastroenterology 1990, 99:416-20.
29. Vogelstein B, Fearon E R, Hamilton S R, Kern S E, Preisinger A C, Leppert M, et al. Genetic alterations during colorectal rumor development. N Engl J Med 1988; 319:525-32.
30. Burmer G C, Loeb L A. Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma. Proc Natl Acad Sci USA 1989, 86:2403-7.
31. Jiang W, Kahn S M, Guillem J G, Lu S-H, Weinstein B. Rapid detection of ras oncogenes in human tumors: application to colon, esophageal, and gastric cancer. Oncogene 1989; 4:923-8.
32. Sidransky D, Tokino T, Hamilton S R, Kinzler K W, Levin B, Frost P, et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992; 256.102-5.
33. Tada M, Omata M, Ohto M. Analysis of ras gene mutations in human hepatic malignant tumors by polymerase chain reaction and direct sequencing Cancer Res 1990, 50:1121-4
34. Smit V T H B M, Boot A J H, Smits A M M, Fleuren G J, Cornelisse C J, Bos J L K-ras codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res 1988; 16:7773-82.
35. Oudejans J J, Slebos R J C, Zoetmulder F A N, Mooi W J, Rodenhuis S Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver. Int J Cancer 1991; 49:875-9
36. Fujita J, Kraus M H, Onoue H, Srivastava S K, Ebi Y, Rhim J S. Activated H-ras oncogenes in human kidney tumors. Cancer Res 1988; 4:5251-5.
37. Vis Vanathan K V, Pocock R D, Summerhayes I C Preferential and novel activation of H-ras in human bladder carcinomas Oncogene Res 1988; 3:77-86
38. Shimizu K, Goldfarb M, Perucho M, Wigler M. Isolation and preliminary characterisation of the transforming gene of a human neuroblastoma cell line Proc Natl Acad Sci USA 1983; 80:383-7.
39. Hirai H, Kobayashi Y, Mano H, Hagiwara K, Maru Y, Omine M, et al. A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome. Nature 1987, 327:430-2.
40. Farr C J, Saiki R K, Ehrlich H A, McCormick F, Marshall C J. Analysis of ras gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes Proc Natl Acad Sci USA 1988; 85:1629-33.
41. Rochlitz C R, Scott G K, Dodson J M, Liu E, Dolbaum C, Smith H S, et al. Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer. Cancer Res 1989; 49.357-60.
42. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988, 53 549-54
43. Gonzalez-Cadavid N F, Zhou D, Battifora H, Bar-Eli M, Cline M J. Direct sequencing analysis of exon 1 of the c-Ki-ras gene shows a low frequency of mutations in human pancreatic adenocarcinomas. Oncogene 1989, 4:1137-40.
44. Sachy B, Zietz C, Rabes H M. K-ras point mutation in human colorectal carcinomas: relation to aneuploidy and metastasis. Int J Cancer 1992; 52:30-3.
45. Bell S M, Scott N, Cross D, Sagar P, Lewis F A, Blair G E, et al. Prognostic value of p53 over-expression and c-Ki-ras gene mutations in colorectal cancer Gastroenterology 1993, 104:57-64.
46. Finkelstein S D, Sayegh R, Christensen S, Swalsky P A. Genotypic classification of colorectal adenocarcinomas. Cancer 1993; 71:3827-38.
47. Delattre O, Olschwang S, Law D J, Melot T, Remivkos Y, Salmon R J, et al. Multiple genetic alterations in distal and proximal colorectal cancer. Lancet 1989; 2:353-6.
48. Burmer G C, Rabinovitch P S, Loeb L A. Analysis of c-Ki-ras mutations in human colon carcinoma by cell sorting, polymerase chain reaction, and DNA sequencing Cancer Res 1989, 49:2141-6
49. Breivik J, Meling G I, Spurkland A, Rognum T O, Gaudernack G. K-ras mutation in colorectal cancer: relations to patient age, sex and tumour location. Br J Cancer 1994; 69:366-71.
50. Moerkerk P, Arends J W, van Driel M, deBruine A, deGoeij A, ten Kate J. Type and number of Ki-ras point mutations relate to stage of human colorectal cancer Cancer Res 1994; 54:3376-8.
51. Elnatan J, Goh H-S, Smith D R. c-Ki-ras activation and the biological behaviour of proximal and distal colonic adenocarcinomas. Eur J Cancer 1996. (In press)
52. Weinberg R A. Tumor suppressor genes Science 1991; 254:1138-46.
53. Vogelstein B, Fearon E R, Kern S E, Hamilton S R, Preisinger A C, Nakamura Y, et al. Allelotype of colorectal carcinomas. Science 1989; 244:207-11
54. Fearon E R, Hamilton S R, Vogelstein B Clonal analysis of colorectal tumors Science 1987, 238:193-7.
55. Solomon E, Voss R, Hall V, Bodmer W F, Jass J R, Jeffreys A J, et al Chromosome 5 allele loss in human colorectal carcinomas. Nature 1987; 328:616-9.
56. Fearon E R, Cho K R, Nigro J M, Kern S E, Simons J W, Ruppert J M, et al Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 1990; 247.49-56.
57. Leister I, Weith A, Bruderlein S, Cziepluch C, Kangwanpong D, Schlag P, et al Human colorectal cancer. High frequency of deletions at chromosome 1p35. Cancer Res 1990; 50:7232-5.
58. Nakamura Y, Lathrop M, Leppert M, Dobbs M, Wasmuth J, Wolff E, et al Localization of the genetic defect in the familial adenomatous polyposis within a small region of chromosome 5. Am J Hum Genet 1988; 43:638-44.
59. Leppert M, Dobbs M, Scambler P, O'Connell P, Nakamura Y, Stauffer D, et al The gene for familial polyposis coli maps to the long arm of chromosome 5. Science 1987; 238:1411-3.
60. Bodmer W F, Bailey C J, Bodmer J, Bussey H J R, Ellis A, Gorman P, et al Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 1989, 328:614-6.
61. Joslyn G, Carlson M, Thliveris A, Albertsen H, Gelbert L, Samowitz W, et al. Identification of deletion mutations and three new genes at the familial polyposis locus. Cell 1991; 66:601-13.
62. Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, et al. Identification and characterisation of the familial adenomatous polyposis gene. Cell 1991; 66:589-600.
63. McBride O W, Merry D, Givol D. The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). Proc Natl Acad Sci USA 1986; 83:7391-4.
64. Isobe M, Emanuel B S, Givol D, Oren M, Croce C. Localisation of the gene for human p53 tumor antigen to band 17p13. Nature 1986; 320:84-5.
65. Baker S J, Fearon E R, Nigro J M, Hamilton S R, Preisinger A C, Jessup J M, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989; 244.217-21
66. Baker S J, Preisinger A C, Jessup J M, Paraskeva C, Markowitz S, Willson J K V, et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 1990; 50:7717-22.
67. Khine K, Smith D R, Goh H-S. High frequency of allelic deletion on chromosome 17p in advanced colorectal cancer Cancer 1994; 73:28-35.
68. Goh H-S, Chan C-S, Khine K, Smith D R. p53 and the behaviour of colorectal cancer Lancet 1994; 344:233-4.
69. Khine K, Goh H-S, Smith D R. Prognostic significance of chromosome 5q and 17p allelic deletion in colorectal adenocarcinomas. Int J Oncol 1995, 7:631-5.
70. Smith D R, Goh H S. p53 and prognosis in colorectal cancer. Ann Acad Med Singapore 1996; 25:107-12.
71. Powell S M, Zilz N, Beazer-Barclay Y, Bryan T M, Hamilton S R, Thibodeau S N, et al. APC mutations occur early during colorectal genesis. Nature 1992; 359:235-7.
72. Ichii S, Takeda S, Horii A, Nakatsuru S, Miyoshi Y, Emi M, et al Detailed analysis of genetic alterations in colorectal tumors from patients with and without familial adenomatous polyposis (FAP). Oncogene 1993; 8:2399-405.
73. Smith D R, Khine K, Chan C-S, Goh H-S. Tumor suppressor genes in colorectal carcinomas: p53 inactivation is highly associated with allelic loss of chromosome 5q. Int J Oncol 1994; 5:539-46.
74. Hollstein M, Sidransky D, Vogelstein B, Harris C C. p53 mutations in human cancers. Science 1991; 253:49-53.
75. Greenblatt M S, Bennett W P, Hollstein M, Harris C C. Mutations in the p53 tumour suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54:4855-78.
76. Levine A J, Perry M E, Chang A, Silver A, Dittmer D, Wu M, et al. The role of the p53 tumor suppressor gene in tumorigenesis. The 1993 Walter Hubert Lecture. Br J Cancer 1994; 69:409-16.
77. Goh H-S, Yao J, Smith D R. p53 point mutation and survival in colorectal cancer patients. Cancer Res 1995, 55:5217-21
78. Vogelstein B, Kinzler K W. p53 function and dysfunction. Cell 1992; 70:523-6
79. Soussi T, Caron de Fromentel C, May P. Structural aspects of the p53 protein in relation to gene evolution Oncogene 1990; 5:945-52.
80. Smith D R, Chan C-S, Goh H-S. A detailed analysis of p53 point mutations in colorectal cancers in Singapore Ann Acad Med Singapore 1994; 23:803-9
81. Dittmer D, Pati S, Zambetti G, Chu S, Teresky A K, Moore M, et al. Gain of function mutations in p53. Nature Genet 1993, 4:42-6.
82. Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remivikos Y, et al Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994; 106:42-8.
83. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Med 1995; 1:1029-34.
84. Lowe S, Bodis S, McClatchey A, Remington L, Ruley H E, Fisher D E, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266:807-10.
85. Derkinderen D J, Boxma O J, Koten J W, den Otter W. Stochastic theory of oncogenesis. Anticancer Res 1990; 10:497-504.
86. Hinds P, Finlay C, Levine A J. Mutation is required to activate the p53 gene for cooperation with ras oncogene and transformation. J Virol 1989; 63:739-46.
87. Smith D R, Elnatan J, Yao J, Goh H-S. Point mutation of the c-Ki-ras protooncogene and the p53 tumour suppressor gene in distal colonic adenocarcinomas. Int J Oncol 1996. (In press)
88. Hermeking H, Eick D. Mediation of c-myc induced apoptosis by p53. Science 1994; 265:2091-3.
89. Tabiti K, Smith D R, Goh H-S, Pallen C J. Increased mRNA expression of the receptor like protein tyrosine phosphatase alpha in late stage colon carcinomas. Cancer Lett 1995; 93:239-48.
90. Smith D R, Ji C-Y, Goh H-S. The prognostic significance of p53 overexpression and point mutation in colorectal adenocarcinoma. Br J Cancer 1996. (In press)
91. Yao J, Goh H-S, Smith D R. p53 mutations in primary colorectal adenocarcinomas and secondary liver deposits. Br J Surg 1996. (In press)
92. Smith D R, Elnatan J, Myint T, Goh H-S. Association of activated oncogenes ras and myc in colorectal carcinomas. Ann Acad Med Singapore 1995; 24:393-8.
93. Smith D R, Khine K, Goh H-S. Allelic loss of the p53 tumour suppressor gene in colorectal cancer. Ann Acad Med Singapore 1995; 24:399-402.